¶ AstraZeneca COVID-19 Vaccine
The AstraZeneca COVID-19 vaccine is a genetic vaccine product developed by AstraZeneca in partnership with Verity Pharmaceutics, the Serum Institute of India (SII) and the University of Oxford. It is known in various contexts as the AstraZeneca-Oxford COVID-19 vaccine, ChAdOx1, ChAdOx1-S or AZD1222 and by its brand names, Vaxzevria or Covishield.
It is one of numerous experimental COVID-19 vaccine products deployed into the global population beginning in 2020 in response to the declared COVID-19 pandemic.
¶ History
In early June 2020, the Bill & Melinda Gates Foundation contributed $750 million to the development of the AstraZeneca-Oxford COVID-19 vaccine.[1] AstraZeneca then partnered with Emergent BioSolutions to manufacture their COVID-19 vaccine product.[2][3]
Health Canada authorized the vaccine under interim order on February 26, 2021.[4]
On May 11, 2021, the Alberta Ministry of Health announced it would no longer offer "first doses" of the AstraZeneca product due to supply issues.[5]
Some 10-15 million doses were discarded at an Emergent Biosolutions plant in Baltimore, Maryland due to suspected contamination. This was followed in March 2021 by Emergeent discarding up to 15 million doses of the Janssen and AstraZeneca COVID-19 vaccines after mixing up ingredients between the two. The mistake was attributed to "human error."[6]
The AstraZeneca COVID-19 vaccine was approved by Health Canada under the Food and Drug Regulations on November 18, 2021.[7]
¶ Documents
- December 16, 2022: Product Monograph
¶ National contracts
South Africa
Between the Serum Institute of India, Serum Life Sciences and the National Department of Health of South Africa.
- January 7, 2021: Term Sheet
- January 16, 2021: Vaccine Purchase Agreement
¶ Clinical trials
- COV001
- COV002
- A Study of a Candidate COVID-19 Vaccine (COV003)
¶ External links
Canellis, D. (2020, June 5). Bill Gates commits $750M to help Oxford vaccinate the world against COVID-19. TNW | Fintech-Ecommerce. http://archive.today/2023.02.25-123239/https://thenextweb.com/news/bill-gates-covid-coronavirus-vaccine-750-million-oxford-azd1222 ↩︎
Blankenship, K. (2020, June 11). AstraZeneca, Emergent BioSolutions sign $87M deal to produce U.S. supply of COVID-19 vaccine. Fierce Pharma. http://archive.today/2022.05.12-232222/https://www.fiercepharma.com/manufacturing/astrazeneca-emergent-biosolutions-sign-87m-deal-to-produce-u-s-supply-covid-vaccine ↩︎
Neri, M. B. (2020, June 11). Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for AstraZeneca’s COVID-19 Vaccine Candidate. Emergent BioSolutions. http://archive.today/2022.05.12-231724/https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-agreement-be-us-manufacturing-0?field_nir_news_date_value[min]= ↩︎
Regulatory Decision Summary - AstraZeneca COVID-19 Vaccine - Health Canada. (2021, February 26). Government of Canada. https://web.archive.org/web/20230610043020/https://covid-vaccine.canada.ca/info/regulatory-decision-summary-detailTwo.html?linkID=RDS00772 ↩︎
Snowdon, W. (2021, May 11). Alberta stops offering first doses of AstraZeneca COVID-19 vaccine due to supply issues. CBC News. http://archive.today/2021.05.11-213711/https://www.cbc.ca/news/canada/edmonton/astrazeneca-covid-19-vaccine-alberta-1.6021739 ↩︎
LaFraniere, S., & Weiland, N. (2021, March 31). Factory Mix-Up Ruins Up to 15 Million Vaccine Doses From Johnson & Johnson. The New York Times. https://web.archive.org/web/20210418220356/https://www.nytimes.com/2021/03/31/us/politics/johnson-johnson-coronavirus-vaccine.html ↩︎
Regulatory Decision Summary - Vaxzevria - Health Canada. (2021, November 18). Government of Canada. https://web.archive.org/web/20230610054136/https://covid-vaccine.canada.ca/info/regulatory-decision-summary-detail.html?linkID=RDS00889 ↩︎